These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8422635)

  • 1. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.
    Ward BG; McGuckin MA; Ramm LE; Coglan M; Sanderson B; Tripcony L; Free KE
    Cancer; 1993 Jan; 71(2):430-8. PubMed ID: 8422635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
    McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
    Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma.
    Gronlund B; Dehn H; Høgdall CK; Engelholm SA; Jørgensen M; Nørgaard-Pedersen B; Høgdall EV
    Int J Gynecol Cancer; 2005; 15(5):836-43. PubMed ID: 16174233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
    Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
    Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
    Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
    Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
    Gronlund B; Høgdall EV; Christensen IJ; Johansen JS; Nørgaard-Pedersen B; Engelholm SA; Høgdall C
    Int J Biol Markers; 2006; 21(3):141-8. PubMed ID: 17013795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of second-look laparotomy for patients with epithelial ovarian carcinoma.
    Kamura T; Tsukamoto N; Saito T; Kaku T; Matsuyama T; Nakano H
    Int J Gynaecol Obstet; 1990 Oct; 33(2):141-7. PubMed ID: 1976547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
    Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
    Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
    Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
    Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
    Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
    Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant.
    Frasci G; Conforti S; Zullo F; Mastrantonio P; Comella G; Comella P; Persico G; Iaffaioli RV
    Cancer; 1996 Mar; 77(6):1122-30. PubMed ID: 8635133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
    Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA-125 monitoring in the management of ovarian cancer.
    Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
    Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.